

Supplementary Table 1. Clinical characteristics of individual participants

Study ID	Age	Gender	Race/ethnicity	Year of HIV diagnosis	Year ART started	Year since uninterrupted ART	Reported nadir	ART regimen	Baseline bulk culture 3BNC117 IC ₅₀
601	56	M	White	1994	1997	2007	350	lopinavir/ritonavir/abacavir/lamivudine	3.03
602	49	M	White	2009	2011	2011	500	raltegravir/emtricitabine/TDF	3.21
603	43	M	White/Hispanic	2003	2005	2005	300	efavirenz/emtricitabine/TDF	0.513
604	29	M	Black	2008	2009	2009	300	emtricitabine/rilpivirine/TDF	2.347
605	36	M	White/Hispanic	2001	2002	2014	372	emtricitabine/rilpivirine/TDF	0.486
608	50	M	Black	1992	2013	2014	250	dolutegravir/ emtricitabine/TDF	>20
609	39	M	White	2014	2014	2014	400	dolutegravir/ emtricitabine/TDF	0.136
610	29	M	White	2011	2012	2012	380	emtricitabine/rilpivirine/TDF	0.324
611	57	M	White	2002	2003	2003	282	emtricitabine/rilpivirine/TDF	1.018
613	50	M	Multiple/Hispanic	1997	1998	2006	300	atazanavir/ritonavir/emtricitabine/TDF	0.996
614	58	M	Black	2000	2000	2000	350	efavirenz/emtricitabine/TDF	>20
615	34	M	Multiple	2011	2011	2011	411	emtricitabine/rilpivirine/TDF	1.142
616	30	M	Black	2004	2005	2005	400	emtricitabine/rilpivirine/TDF	0.371
618	26	M	Black	2014	2015	2015	450	abacavir/dolutegravir/lamivudine	1.96
619	53	F	Black	1992	1995	2013	280	elvitegravir/cobicistat/emtricitabine/TAF	0.59